Bedaquiline: a review of human pharmacokinetics and drug-drug interactions

Bedaquiline has recently been approved for the treatment of pulmonary multidrug-resistant tuberculosis (TB) as part of combination therapy in adults. It is metabolized primarily by the cytochrome P450 isoenzyme 3A4 (CYP3A4) to a less-active N-monodesmethyl metabolite. Phase I and Phase II studies in...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of antimicrobial chemotherapy Jg. 69; H. 9; S. 2310
Hauptverfasser:	van Heeswijk, R P G, Dannemann, B, Hoetelmans, R M W
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England 01.09.2014
Schlagworte:	Antifungal Agents - pharmacology Antitubercular Agents - pharmacokinetics Antitubercular Agents - pharmacology Antiviral Agents - pharmacology Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Diarylquinolines - pharmacokinetics Diarylquinolines - pharmacology Drug Interactions Humans Tuberculosis, Multidrug-Resistant - drug therapy CYP3A clinical trials HIV tuberculosis
ISSN:	1460-2091, 1460-2091
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!